Barr Pharmaceuticals announced today that the FDA has approved its abbreviated new drug application (ANDA088640), acquiring rights to a discontinued drug product with potential imminently available generic competition. Market watchers anticipate the introduction of this generic will drive price erosion and shift market share as the patent protection for the brand-name reference product expires.